10-Q: PepGen Reports Q2 2026 Results, Focuses on PGN-EDODM1

PepGen Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued research and development expenses, progress on its PGN-EDODM1 candidate, and a partial clinical hold in the U.S.

Summary

• PepGen Inc. reported its financial results for the quarter and six months ended June 30, 2026.
• The company incurred net losses of $17.8 million for the three months ended June 30, 2026, and $35.6 million for the six months ended June 30, 2026.
• Research and development expenses decreased significantly compared to the prior year, primarily due to the discontinuation of the PGN-EDO51 program.
• The company's lead product candidate, PGN-EDODM1, is in Phase 2 clinical development for Duchenne muscular dystrophy (DM1).
• A partial clinical hold remains in place for the FREEDOM2 study in the U.S., with the company working to address FDA questions.
• As of June 30, 2026, PepGen had $117.2 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the fourth quarter of 2027.
• The company continues to rely on equity financings and other capital sources to fund its operations.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as cautiously negative due to continued operating losses, a partial clinical hold in the U.S., and the need for future capital raises, despite progress in clinical trials.

Positives

• PGN-EDODM1 showed dose-dependent mean splicing correction of up to 53.7% in Phase 1 studies.
• PGN-EDODM1 was generally well-tolerated in clinical trials, with no serious adverse events reported in the 5 mg/kg cohort of FREEDOM2.
• The company has sufficient cash to fund operations into the fourth quarter of 2027.
• Orphan drug designation and Fast Track designation have been granted by the FDA for PGN-EDODM1.
• The EMA has also granted orphan medicinal product designation to PGN-EDODM1.

Negatives

• The company incurred net losses of $17.8 million and $35.6 million for the three and six months ended June 30, 2026, respectively.
• The FREEDOM2 study remains on partial clinical hold in the U.S., impacting U.S. site initiation.
• The company has not generated any revenue from product sales and expects to continue incurring losses.
• The company will need to raise substantial additional funding to continue operations and product development.
• Splicing correction in the FREEDOM2 study's 5 mg/kg cohort was lower (7.3%) compared to the Phase 1 study (12.7% at 5 mg/kg), though an outlier patient skewed the FREEDOM2 result.
• The company voluntarily discontinued development of PGN-EDO51.

Risks

• Substantial dependence on the success of PGN-EDODM1; failure to complete development or obtain approval would harm the business.
• Incurrence of significant losses since inception and expectation of continued losses for the foreseeable future.
• Need for substantial additional funding, with a risk of delay, scaling back, or discontinuation of development programs if unable to raise capital.
• The partial clinical hold on the FREEDOM2 study in the U.S. could negatively impact enrollment timelines.
• Uncertainty in clinical trial outcomes, including potential for adverse side effects or failure to demonstrate safety and effectiveness.
• Reliance on third parties for manufacturing, research, and clinical testing, with risks of unsatisfactory performance or supply disruptions.
• Competition from other therapies and product candidates in development.
• Potential failure to obtain or maintain patent protection for the EDO platform and product candidates.

Future Outlook

The company believes its current cash, cash equivalents, and marketable securities will be sufficient to fund its planned operations into the fourth quarter of 2027. However, it expects expenses and operating losses to continue as it advances PGN-EDODM1, conducts research, utilizes third parties for manufacturing, hires personnel, protects intellectual property, and incurs public company costs. Future funding is expected through equity offerings, debt financings, or other capital sources, but there is no assurance of availability on acceptable terms.

Management Comments

• Stock-based compensation expense associated with stock options, RSUs, PSUs, and the Company's ESPP is detailed.
• The company's management evaluated the effectiveness of disclosure controls and procedures and found them to be effective at a reasonable assurance level as of June 30, 2026.

Industry Context

StockSavvy.ai notes that PepGen operates in the highly competitive clinical-stage biotechnology sector, focusing on oligonucleotide therapeutics for severe neuromuscular and neurological diseases. The company's progress with PGN-EDODM1 and its EDO platform aligns with industry trends in targeted genetic therapies, but faces significant challenges common to early-stage biotechs, including clinical trial risks, regulatory hurdles, and substantial capital requirements.

Comparison to Industry Standards

• PepGen's R&D expenses as a percentage of total operating expenses are high, typical for clinical-stage biotech companies investing heavily in pipeline development.
• The company's net loss per share of ($0.26) for the quarter is within the range expected for companies at this stage of development, though it indicates a continued need for funding.
• The cash burn rate, while significant, is being managed with a stated runway into late 2027, which is a critical metric for investors in this sector.

Legal Proceedings

• A putative shareholder class action was filed on June 9, 2025, but was voluntarily dismissed by stipulation on November 18, 2025.
• A subsequent shareholder demand based on similar allegations was withdrawn on December 1, 2025.
• The company is not currently a party to any other material legal proceedings.

Related Party Transactions

• Technology License Agreement with Oxford University Innovation Limited and Medical Research Council of United Kingdom Research and Innovation.
• Oxford Science Enterprises (OSE), an affiliate of OUI, owned 7.2% of outstanding common stock as of June 30, 2026.
• Entities affiliated with RA Capital Management, L.P. owned 29.0% of outstanding common stock as of June 30, 2026.
• Two board members, Dr. Joshua Resnick and Habib Dable, are affiliated with RA Capital.
• Fees paid to RA Capital for Dr. Resnick's board service were $11,000 for the three months and $22,000 for the six months ended June 30, 2026.

Stakeholder Impact

• Shareholders may experience continued stock price volatility due to ongoing clinical development, regulatory hurdles, and financing needs.
• Employees' stock-based compensation is detailed, with unrecognized costs related to stock options and RSUs.
• Potential future commercialization of PGN-EDODM1 could impact patients with DM1 by offering a new therapeutic option.

Next Steps

• Continue clinical development of PGN-EDODM1.
• Address questions raised by the FDA regarding the partial clinical hold on the FREEDOM2 study in the U.S.
• Report data from the 10 mg/kg cohort of the FREEDOM2 study in November 2026.
• Report data from the 12.5 mg/kg cohort of FREEDOM2 in the first half of 2027.
• Continue to manage cash resources and pursue additional financing as needed.

Key Dates

Recommendation

PepGen remains a speculative investment due to its clinical-stage nature and ongoing need for capital. While PGN-EDODM1 shows promise in early data, the partial clinical hold in the U.S. and the lower-than-expected splicing correction in one FREEDOM2 cohort warrant caution. The company's cash runway is adequate for now, but future financing needs and the success of upcoming clinical data readouts are critical. Investors should hold positions while monitoring clinical progress and regulatory developments.

Keywords

biotechnology, clinical-stage, oligonucleotide therapeutics, neuromuscular diseases, neurologic diseases, PGN-EDODM1, Duchenne muscular dystrophy, clinical trials